文献速递肾移植

肾移植受者SARS-CoV-2感染后IgG而非IgA抗刺突抗体动力学延迟

Delayed Kinetics of IgG, but Not IgA, Antispike Antibodies in Transplant Recipients following SARS-CoV-2 Infection.
PubMed 文献 · J Am Soc Nephrol · 2021-12-01

该横断面研究纳入49例肾移植受者和42例免疫正常对照,在SARS-CoV-2感染早期(≤14天)或晚期(>14天)检测针对5种病毒表位的IgM、IgG、IgG1-4和IgA抗体。肾移植受者早期总IgG抗三聚体刺突、S1、S2和受体结合域(RBD)水平低于晚期,也低于免疫正常对照;但IgM和IgA抗刺突、S1、RBD或S2的动力学无显著差异。结论:肾移植受者早期IgA和IgM应答存在,但IgG应答较免疫正常个体延迟。

要点

  • 肾移植受者感染SARS-CoV-2后早期IgG抗刺突蛋白水平低于免疫正常对照。
  • 肾移植受者IgG应答延迟,而IgA和IgM动力学与对照无显著差异。
  • 抗SARS-CoV-2抗体以IgG1和IgG3为主,向IgG2或IgG4类转换有限。

核心结论

  • 肾移植受者SARS-CoV-2感染后早期IgA和IgM应答存在,但IgG应答较免疫正常个体延迟。

研究设计与样本

  • 横断面研究,纳入49例肾移植受者和42例免疫正常对照,在感染后早期(≤14天)或晚期(>14天)检测抗体。

主要发现

  • 肾移植受者早期总IgG抗三聚体刺突、S1、S2和RBD水平低于晚期,也低于免疫正常对照。
  • 晚期IgG抗刺突、S1、S2、RBD和核衣壳(NC)水平在两组间无显著差异。
  • IgM或IgA抗刺突、S1、RBD或S2的动力学按诊断后时间或移植状态无显著差异。
  • 抗SARS-CoV-2抗体以IgG1和IgG3为主,向IgG2或IgG4类转换有限。

临床怎么用

  • 肾移植受者COVID-19后早期IgG可能尚未升高,解读抗体结果时需考虑感染后时间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Kidney transplant recipients are at increased risk of severe outcomes during COVID-19. Antibodies against the virus are thought to offer protection, but a thorough characterization of anti-SARS-CoV-2 immune globulin isotypes in kidney transplant recipients following SARS-CoV-2 infection has not been reported. METHODS: We performed a cross-sectional study of 49 kidney transplant recipients and 42 immunocompetent controls at early (≤14 days) or late (>14 days) time points after documented SARS-CoV-2 infection. Using a validated semiquantitative Luminex-based multiplex assay, we determined the abundances of IgM, IgG, IgG1-4, and IgA antibodies against five distinct viral epitopes. RESULTS: Kidney transplant recipients showed lower levels of total IgG antitrimeric spike (S), S1, S2, and receptor binding domain (RBD) but not nucleocapsid (NC) at early versus late time points after SARS-CoV-2 infection. Early levels of IgG antispike protein epitopes were also lower than in immunocompetent controls. Anti-SARS-CoV-2 antibodies were predominantly IgG1 and IgG3, with modest class switching to IgG2 or IgG4 in either cohort. Later levels of IgG antispike, S1, S2, RBD, and NC did not significantly differ between cohorts. There was no significant difference in the kinetics of either IgM or IgA antispike, S1, RBD, or S2 on the basis of timing after diagnosis or transplant status. CONCLUSIONS: Kidney transplant recipients mount early anti-SARS-CoV-2 IgA and IgM responses, whereas IgG responses are delayed compared with immunocompetent individuals. These findings might explain the poor outcomes in transplant recipients with COVID-19. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/JASN/2021_11_23_briggsgriffin112321.mp3.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Cravedi P, Ahearn P, Wang L, et al. Delayed Kinetics of IgG, but Not IgA, Antispike Antibodies in Transplant Recipients following SARS-CoV-2 Infection. J Am Soc Nephrol. 2021. PMID: 34599041. doi:10.1681/ASN.2021040573

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。